Cagrilintide/semaglutide
REDEFINE 1
Novo Nordisk · Phase 3 · Active, not recruiting · Enrollment 3400
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Cagrisema | Obesity, no T2D | cagrilintide 2.4 mg and semaglutide 2.4 mg | 68 | n/r | -20.4% at week 68 |
| Cagrilintide | Population n/r | n/r | n/r | n/r | n/r |
| Semaglutide | Population n/r | n/r | n/r | n/r | n/r |
| Placebo s.c. | Obesity, no T2D | n/r | 68 | n/r | -3% at week 68 |